Cisplatinum may be synergistic if used in combination with other agents. This study was undertaken to investigate whether a mitomycin plus cisplatin in combination could show any promising data in colorectal cancer. The regimen did not show sufficient activity to encourage further trials.
Get full access to this article
View all access options for this article.
References
1.
BergeratJ.P., DrewinkoB., CorryP., BarlogieB., HoD.H.: Synergistic lethal effect of cisdichlorodiammineplatinum and 1-etha-o-arabinofuranosylcytosine.Cancer Res., 41: 25–30, 1981.
MillerA.B., HoagstratenB., StaquetM., WinklerA.: Reporting results of cancer treatment.Cancer, 47: 207–214, 1981.
4.
RozencweigM., BleibergH., KenisY.: Mitomycin-C therapy in advanced colorectal cancer. In: Mitomycin-C, Current Impact on Cancer Chemotherapy.OgawaM., RozencweigM., StaquetM.J. (eds.), Excerpta Medica, Amsterdam, pp. 76–88, 1982.
5.
SchabelF.M.Jr., TraderM.V., LasterW.R., LorbettT.H., GrinswaldD.P.Jr.: Cisdichlorodiammineplatinum (II): combination chemotherapy and cross-resistance studies with tumors of mice.Cancer Treat. Rep., 63: 1459–1473, 1979.
